<?xml-stylesheet type="text/xsl" href="ViewNLM-v2.3.xsl"?>
<!DOCTYPE article
PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Asia Pac Allergy</journal-id><journal-id journal-id-type="publisher-id">APA</journal-id><journal-title-group><journal-title>Asia Pacific Allergy</journal-title></journal-title-group><issn pub-type="ppub">2233-8276</issn><issn pub-type="epub">2233-8268</issn><publisher><publisher-name>Asia Pacific Association of Allergy, Asthma and Clinical Immunology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">3269605</article-id><article-id pub-id-type="pmid">22348210</article-id><article-id pub-id-type="doi">10.5415/apallergy.2012.2.1.76</article-id><article-categories><subj-group subj-group-type="heading"><subject>Educational &#x00026; Teaching Material</subject></subj-group></article-categories><title-group><article-title>Magnesium sulfate for acute asthma in adults: a systematic literature review</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Song</surname><given-names>Woo-Jung</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Chang</surname><given-names>Yoon-Seok</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref><xref ref-type="aff" rid="A3">3</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Internal Medicine, Seoul National University College of Medicine, Seoul 110-799, Korea.</aff><aff id="A2"><label>2</label>Institute of Allergy and Clinical Immunology, Seoul National University Medical Research Center, Seoul 110-799, Korea.</aff><aff id="A3"><label>3</label>Division of Allergy and Clinical Immunology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam 463-802, Korea.</aff><author-notes><corresp>
Correspondence: Yoon-Seok Chang. Department of Internal Medicine, Seoul National University Bundang Hospital, 300 Gumi-dong, Bundang-gu, Seongnam 463-802, Korea. Tel: +82-31-787-7023, Fax: +82-31-787-4052, <email>addchang@snu.ac.kr</email></corresp></author-notes><pub-date pub-type="ppub"><month>1</month><year>2012</year></pub-date><pub-date pub-type="epub"><day>31</day><month>1</month><year>2012</year></pub-date><volume>2</volume><issue>1</issue><fpage>76</fpage><lpage>85</lpage><history><date date-type="received"><day>20</day><month>12</month><year>2011</year></date><date date-type="accepted"><day>28</day><month>12</month><year>2011</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2012. Asia Pacific Association of Allergy, Asthma and Clinical Immunology.</copyright-statement><copyright-year>2012</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Magnesium sulfate (MgSO<sub>4</sub>) has been considered as an adjunct therapy for severe and life-threatening asthma exacerbation. The literature search was performed using MEDLINE, EMBASE, Cochrane Library and Google Scholar to summarize the current state of knowledge regarding magnesium therapy in acute exacerbation of adult asthma. A total of 16 trials and 4 meta-analyses were identified. As results, intravenous MgSO<sub>4</sub> was beneficial in severe exacerbation, but evidence for nebulized magnesium was insufficient. However, larger trials are required to draw confirmative conclusions on the efficacy. Regarding the safety concern, the risk of major toxicity appears to be very low at usual doses described in the literature. Additionally, results from 4 surveys were examined on the gaps between knowledge and practice, and on the barrier to the use of MgSO<sub>4</sub> at emergency departments. This literature review summarized the up-to-date evidence on the issues regarding the use of MgSO<sub>4</sub> for acute asthma. We expect more studies to be conducted for evidence making in the Asian-Pacific regions.</p></abstract><kwd-group><kwd>Asthma</kwd><kwd>Magnesium sulfate</kwd><kwd>Emergency treatment</kwd><kwd>Review</kwd></kwd-group></article-meta></front><body><sec><title>INTRODUCTION</title><p>Magnesium sulfate (MgSO<sub>4</sub>) has been considered as an adjunct therapy for severe and life-threatening asthma exacerbation. Theoretically, magnesium can induce bronchial smooth muscle relaxation in a dose-dependent manner [<xref ref-type="bibr" rid="B1">1</xref>] by inhibiting calcium influx into the cytosol [<xref ref-type="bibr" rid="B2">2</xref>], histamine release from mast cells [<xref ref-type="bibr" rid="B3">3</xref>], or acetylcholine release from cholinergic nerve endings [<xref ref-type="bibr" rid="B4">4</xref>]. It also may increase the bronchodilator effect of &#x003b2;<sub>2</sub>-agonist by increasing the receptor affinity [<xref ref-type="bibr" rid="B5">5</xref>]. Historically, in the literature, the first description on the clinical use of magnesium for asthma was reported in 1936 [<xref ref-type="bibr" rid="B6">6</xref>]. In 1987, Okayama et al. [<xref ref-type="bibr" rid="B7">7</xref>] reported rapid bronchodilating effects of intravenous (IV) MgSO<sub>4</sub> infusion in 10 asthma patients. In 1989, its effect was also reported for prevention of endotracheal intubation and mechanical ventilation in an elderly asthma patient with severe exacerbation [<xref ref-type="bibr" rid="B8">8</xref>].</p><p>The first randomized controlled trial (RCT) was conducted in 1989 by Skobeloff et al. [<xref ref-type="bibr" rid="B9">9</xref>] to investigate its efficacy. Since then, it has been examined by several RCTs and meta-analyses. At the same time, the use of nebulized MgSO<sub>4</sub> has also gained scientific interests. Current guidelines [<xref ref-type="bibr" rid="B10">10</xref>-<xref ref-type="bibr" rid="B12">12</xref>] suggest the use of IV MgSO<sub>4</sub> as an adjunct therapy to improve pulmonary functions and reduce hospital admission in certain patients with severe and life-threatening acute exacerbations unresponsive to initial treatments, whereas the evidence has been weaker for nebulized magnesium.</p><p>In this review, we aimed to summarize the current state of knowledge regarding the use of MgSO<sub>4</sub> in acute exacerbation of adult asthmatics.</p><sec><title>Key question</title><p>Population: adult asthma patients with acute exacerbation</p><p>Intervention: MgSO<sub>4</sub> (intravenous or nebulized form)</p><p>Control: placebo</p><p>Outcome: clinical efficacy</p></sec><sec><title>Search strategy</title><p>The literature search was performed during the period September 2011 until December 2011. Articles were searched from MEDLINE, EMBASE, the Cochrane Library and Google Scholar. Search terms included the terms for asthma, exacerbation and magnesium. Additionally, manual searching the references for relevant articles was also performed on respiratory or emergency medicine journals. The search for unpublished data was not conducted. The search was limited to the last 25 years (1986 to 2011).</p><p>First, authors scanned titles, abstracts, and selected relevant articles for retrieval of full-text. Through a full-text review, final selection was made: RCTs were included if they were conducted on adult acute asthmatics and compared its efficacy with placebo. The quality of included RCTs were determined by the five point Jadad score [<xref ref-type="bibr" rid="B13">13</xref>]. Meta-analyses were included if they included the issues relevant to our key question. Suspected duplicates were excluded. Finally, 10 RCTs for IV MgSO<sub>4</sub>, 6 RCTs for nebulized MgSO<sub>4</sub>, and 4 meta-analyses were included. All the identified articles were originally written in English, although attempts were made to find out non-English sources including Korean and Japanese.</p></sec><sec><title>Data extraction</title><p>The following data were extracted: study design, study population (patients, or number of pooled trials), interventions, control, co-treatments, and outcomes of interest.</p></sec><sec><title>Additional search</title><p>Articles were searched again from the same electronic databases to retrieve information on the practice status at emergency departments regarding the use of MgSO<sub>4</sub> in acute asthma patients. This search was not limited to adult population, because studies were scarce. Finally, 4 original articles were selected.</p></sec><sec><title>Included studies</title><p>Included RCTs were summarized in <xref ref-type="table" rid="T1">Tables 1</xref> and <xref ref-type="table" rid="T2">2</xref>. Overall quality of RCTs was high, having a Jadad score of 4 or 5 in 11/16 trials. The majority (13/16) of the studies were double-blinded, while two trials [<xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B15">15</xref>] for IV and one trial [<xref ref-type="bibr" rid="B16">16</xref>] for nebulized MgSO<sub>4</sub> were single-blinded. However, heterogeneity was identified for the included trials. For RCTs on IV form, there were variations in the severity of attack, definition of severity, treatment dose (2 g bolus in 6/10 trials), co-treatments (IV theophylline/aminophylline in 5/10 trials, and nebulized ipratropium in 2/10 trials), and timing to measure outcomes. As for nebulized form, there was notable heterogeneity in the treatment dose of nebulized MgSO<sub>4</sub>.</p><p>The included meta-analyses were described in <xref ref-type="table" rid="T3">Table 3</xref>. A meta-analysis by Mohammed et al. [<xref ref-type="bibr" rid="B17">17</xref>] was the most up-to-date and comprehensive one including most of published RCTs and also unpublished data such as conference abstracts. Three recently published RCTs [<xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B18">18</xref>, <xref ref-type="bibr" rid="B19">19</xref>], not included in the meta-analyses, had distinct points from previous trials in that the recent trials used nebulized ipratropium as one of the routine treatments.</p></sec><sec><title>Efficacy of intravenous MgSO<sub>4</sub></title><p>There have been 3 meta-analyses and 2 recent RCTs. The results from the Cochrane review by Rowe et al. [<xref ref-type="bibr" rid="B20">20</xref>] stated that IV MgSO<sub>4</sub> as adjunct to standard treatment was beneficial in severe acute asthma patients, both in terms of pulmonary functions and hospital admission rate. The results by Rodrigo et al. [<xref ref-type="bibr" rid="B21">21</xref>] were not concordant, but the number of pooled studies and patients were smaller than the Cochrane review. The recent reviews by Mohammed et al. [<xref ref-type="bibr" rid="B17">17</xref>] found that the efficacy was only marginal on pulmonary function (standardized mean difference (SMD) 0.25, 95% confidence interval (CI) -0.01 to 0.51), and not significant on hospital admission (relative risk (RR) 0.87, 95% CI 0.70 to 1.08). However, their analyses were not confined to severe exacerbations.</p><p>Notably, two recent RCTs used nebulized ipratropium bromide as their standard treatments. The trials by Bradshaw et al. [<xref ref-type="bibr" rid="B19">19</xref>] did not show additional benefit of 1.2 g IV MgSO<sub>4</sub> even in subgroups of life-threatening exacerbation. However, the trials by Singh et al. [<xref ref-type="bibr" rid="B15">15</xref>] showed its positive effect on forced expiratory volume in 1 second (FEV1) % predicted (vs. placebo; mean difference 6.07, 95% CI 1.87 to 10.62), but had limitations in smaller number of participants and single-blinded design.</p><p>Nebulized ipratropium is currently recommended as an additional bronchodilator for moderate exacerbation by guidelines, and is being widely used in practice. Therefore, the efficacy of IV MgSO<sub>4</sub> needs to be examined further in the context of current treatment guidelines. Nevertheless, the use of MgSO<sub>4</sub> should not be hesitated in patients with severe life-threatening asthma exacerbation unresponsive to standard treatments, because its toxicity was minimal.</p></sec><sec><title>Efficacy of nebulized MgSO<sub>4</sub></title><p>There have been 2 meta-analyses and 1 recent RCT. The Cochrane review conducted by Blitz et al. [<xref ref-type="bibr" rid="B22">22</xref>] showed that nebulized MgSO<sub>4</sub> improved pulmonary functions (SMD 0.55, 95% CI 0.12 to 0.98) in severe subgroups (FEV1 or peak expiratory flow &#x0003c;50% predicted). However, the results were based on only 87 adult asthmatics from 2 trials. The recent reviews by Mohammed et al. [<xref ref-type="bibr" rid="B17">17</xref>] examined more trials and found that nebulized MgSO<sub>4</sub> had marginal benefits on pulmonary functions (SMD 0.17, 95% CI -0.02 to 0.36) and on hospital admission rate (RR 0.68, 95% CI 0.46 to 1.02). Considering the heterogeneity in treatment doses, severity of patients and small numbers of pooled studies, they concluded that evidence is insufficient to draw conclusions.</p><p>In a recent trial (n = 60) by Gallegos-Sol&#x000f3;rzano et al. [<xref ref-type="bibr" rid="B18">18</xref>], when added to standard treatments of nebulized albuterol and ipratropium, nebulized MgSO<sub>4</sub> therapy improved post-bronchodilator lung functions and oxygen saturation, and reduced admission rates at 90 min. However, the largest trial (n = 100) by Aggarwal et al. [<xref ref-type="bibr" rid="B23">23</xref>] failed to show any benefit of additional MgSO<sub>4</sub> therapy. Taken together, the use of nebulized MgSO<sub>4</sub> might be beneficial in treating severe exacerbation, but large trials are required for more definite conclusion.</p></sec><sec><title>Formulation and optimal dose</title><p>The dose of IV magnesium was 2 g as a bolus in most trials showing its effectiveness. The Cochrane review examined the safety of 2 g magnesium to find out its minimal risk of significant adverse reaction [<xref ref-type="bibr" rid="B20">20</xref>]. A RCT [<xref ref-type="bibr" rid="B6">6</xref>] using 2 g reported no major toxicities but only minor ones in 58% of patients (sensation of flushing, mild fatigue and burning sense at IV site). In a trial using 1.2 g bolus [<xref ref-type="bibr" rid="B13">13</xref>], the rate of minor side effect was 8% (headache, flushing and dizziness).</p><p>For more than two decades, magnesium has been used as a tocolytic agent for preterm labor, at higher doses (such as a 6 g IV load over 20 min and followed by a continuous infusion of 2 to 4 g/h [<xref ref-type="bibr" rid="B24">24</xref>]). Major toxicity occurred at serum magnesium level of 9 mg/dL or higher, such as loss of reflexes, blurred vision, lethargy, muscle weakness or pulmonary edema [<xref ref-type="bibr" rid="B24">24</xref>]. However, magnesium is usually excreted in urine, and administration of 2 g in a bolus increases the concentration just from 2.2 to 2.8 mg/dL 30 min after the infusion [<xref ref-type="bibr" rid="B25">25</xref>]. Therefore, it can be concluded that the usual dose of 2 g for acute asthma has a minimal risk of major toxicity in patients with normal renal function, as suggested by the meta-analyses [<xref ref-type="bibr" rid="B20">20</xref>]. The possibility exists that higher dose of IV magnesium is more effective, but still no published report has directly examined the benefit from high dose bolus therapy such as 4 g. One trial evaluated the role of continuous MgSO<sub>4</sub> infusion, but failed to find its additional benefit [<xref ref-type="bibr" rid="B26">26</xref>].</p><p>Hypermagnesemia can be managed by prompt cessation of magnesium infusion in patients with normal renal functions. However, hemodialysis and IV calcium gluconate may be required in high risk patients with renal dysfunctions, bowel obstruction [<xref ref-type="bibr" rid="B27">27</xref>], or in elderly patients taking magnesium-containing cathartics [<xref ref-type="bibr" rid="B28">28</xref>].</p><p>In cases of nebulized magnesium, optimal dosing may be more intricate. MgSO<sub>4</sub> is administered by a nebulizer, as a vehicle for &#x003b2;2-agonist (and also as in combination). However, hypertonic or hypotonic nebulized solution can cause bronchoconstriction by itself in asthmatics [<xref ref-type="bibr" rid="B29">29</xref>, <xref ref-type="bibr" rid="B30">30</xref>]. Therefore, larger dose of magnesium may not be feasible due to practical reasons such as nebulizer volume, or the need for specific concentration of MgSO<sub>4</sub> to make an isotonic solution. For example, in a trial by Aggarwal et al. [<xref ref-type="bibr" rid="B23">23</xref>], they made magnesium-containing solutions (10 mL, 295 mosmol/kg) as following: 1 mL of salbutamol solution, 1 mL of MgSO<sub>4</sub> (from IV preparation at concentration of 500 mg/mL), plus 8 mL distilled water.</p><p>At the moment, there is no available evidence to advocate the use of higher dose of nebulized magnesium for yielding a better efficacy. Moreover, no dose-response relationships (from 0 to 360 mg MgSO<sub>4</sub>) have been reported [<xref ref-type="bibr" rid="B31">31</xref>]. Nebulized MgSO<sub>4</sub> therapy can be considered as safe, because no serious side effects were reported [<xref ref-type="bibr" rid="B22">22</xref>].</p></sec><sec><title>Monitoring serum magnesium levels</title><p>As pre-existing magnesium deficit could be associated with risk of asthma exacerbation [<xref ref-type="bibr" rid="B32">32</xref>-<xref ref-type="bibr" rid="B35">35</xref>], one might think that serum magnesium level could be measured for adequate supplementation or prediction of treatment response. However, it is predominantly an intracellular ion, and its serum level does not reflect intracellular concentrations or total body stores. Its intracellular concentration was found to be lower in acute exacerbation and returned to normal when controlled, while plasma level remained unchanged [<xref ref-type="bibr" rid="B36">36</xref>]. Therefore, serum level does not represent the degree of cellular deficit, and it would not be useful to monitor serum magnesium level for enhancing the efficacy of MgSO<sub>4</sub> therapy.</p></sec><sec><title>Gap and barrier to the use of MgSO<sub>4</sub></title><p>Current guidelines [<xref ref-type="bibr" rid="B10">10</xref>-<xref ref-type="bibr" rid="B12">12</xref>] suggest the use of IV MgSO<sub>4</sub> as an adjunct to standard treatment in acute severe exacerbations (<xref ref-type="table" rid="T4">Table 4</xref>). Four observational studies evaluated the implementation of treatment guidelines with regard to the use of MgSO<sub>4</sub> (<xref ref-type="table" rid="T5">Table 5</xref>). They were conducted in North America, UK, Australia and New Zealand.</p><p>In North America, a large-scale study [<xref ref-type="bibr" rid="B37">37</xref>] was conducted on patient cohorts and emergency physicians to investigate the use of IV MgSO<sub>4</sub>. Among 9745 emergency department (ED) patients, only 2.5% received IV MgSO<sub>4</sub>. In logistic regression analyses, its use was associated with older age, previous intubation history, higher respiratory rate, lower initial pulmonary functions, higher number of &#x003b2;<sub>2</sub>-agonists use, and use of systemic corticosteroids. For physicians at ED, 92% had MgSO<sub>4</sub> available and 64% had recently used it. They tipped severity (96%) and poor response to initial &#x003b2;<sub>2</sub>-agonists (87%) as main factors prompting the use of MgSO<sub>4</sub>.</p><p>In an online survey of two national pediatric ED physicians in North America [<xref ref-type="bibr" rid="B38">38</xref>], 88% of physicians knew the efficacy of IV MgSO<sub>4</sub>, but 37.7% of physicians did not use IV MgSO<sub>4</sub> in the management of severe acute asthma. Main barriers to the use were lack of needs (31%) and concerns of side effects (24%).</p><p>In a postal survey undertaken for all adult EDs within the UK [<xref ref-type="bibr" rid="B39">39</xref>], IV MgSO<sub>4</sub> was currently being used in 93% of EDs, and more than 80% of severe or life-threatening asthma patients received the therapy. The reasons for using the agent were to improve breathlessness (70%) or reduce admissions (51%). Nebulized MgSO<sub>4</sub> was being rarely used (1%), and the main reason was insufficient evidence (51%).</p><p>In a study conducted in Australia and New Zealand [<xref ref-type="bibr" rid="B40">40</xref>], they compared the gaps between clinical practice guideline (CPG) recommendations and self-reported physician management from 11 pediatric EDs. The gap between CPG and practice was particularly wide for severe to critical asthma. For IV MgSO<sub>4</sub>, it has been utilized in the practice for 7.7% of severe asthma and 55.1% of critical asthma (in CPG: 18.2% and 45.5%, respectively). The limitation of this study was that discrepancy existed between New Zealand and Australian guidelines on the recommendation of the use of magnesium.</p><p>Taken together, overall degree of knowledge among ED physicians appears to be high among examined countries. However, the significant gaps were found between the knowledge and the practice patterns except UK.</p></sec><sec><title>Studies from the Asia-Pacific regions</title><p>There have been four RCTs on the efficacy of MgSO<sub>4</sub> from the Asia-Pacific regions (two from India, and Iran and Thailand for each). Their results were conflicting, but did not have notable differences from Western studies in their study designs or outcome measures. No information was available to determine ethnic differences on the efficacy of MgSO<sub>4</sub> therapy. However, IV aminophylline has been used at EDs more widely in Korea and Japan than Western countries due to belief that the agent is not very toxic for the Northeast Asian people such as the Korean or the Japanese. In a Japanese prospective safety survey conducted by Ohta et al. [<xref ref-type="bibr" rid="B41">41</xref>], IV aminophylline treatment was found to be highly safe among the Japanese adult patients (age: 15-65 years) when administered in accordance with the guidelines and instructions. Its toxicity occurred in 0.29% of 682 patients, and all of them were mild. Thus we guess that the needs for an adjunct magnesium therapy might be lower in the Northeast Asia region than Western countries.</p><p>We have no more information on the current status of knowledge and practice regarding the use of MgSO<sub>4</sub> for acute asthma in this region.</p></sec></sec><sec><title>CONCLUSION</title><p>IV MgSO<sub>4</sub> as an adjunct to standard treatment may be beneficial in the treatment of adult patients with severe or life-threatening exacerbation. The role of nebulized MgSO<sub>4</sub> is less evident due to insufficient evidence. The use of MgSO<sub>4</sub> has excellent safety profile if appropriately administered. Studies are needed to investigate its role and to identify the gaps between guidelines and practice patterns in the Asia-Pacific region.</p></sec></body><back><ack><title>ACKNOWLEDGEMENTS</title><p>This study was supported by grants of the Korean Healthcare technology R&#x00026;D Project, Ministry of Health, Welfare, Republic of Korea (A102065). The authors thank the committee members of Korean Asthma Management Guideline for Adults, especially, professor Sang-Heon Cho, professor Sae-Hoon Kim from Seoul National University, and professor Soo Young Kim from Hallym University.</p></ack><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spivey</surname><given-names>WH</given-names></name><name><surname>Skobeloff</surname><given-names>EM</given-names></name><name><surname>Levin</surname><given-names>RM</given-names></name></person-group><article-title>Effect of magnesium chloride on rabbit bronchial smooth muscle</article-title><source>Ann Emerg Med</source><year>1990</year><volume>19</volume><fpage>1107</fpage><lpage>1112</lpage><pub-id pub-id-type="pmid">1977337</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gourgoulianis</surname><given-names>KI</given-names></name><name><surname>Chatziparasidis</surname><given-names>G</given-names></name><name><surname>Chatziefthimiou</surname><given-names>A</given-names></name><name><surname>Molyvdas</surname><given-names>PA</given-names></name></person-group><article-title>Magnesium as a relaxing factor of airway smooth muscles</article-title><source>J Aerosol Med</source><year>2001</year><volume>14</volume><fpage>301</fpage><lpage>307</lpage><pub-id pub-id-type="pmid">11693841</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bois</surname><given-names>P</given-names></name></person-group><article-title>Effect of magnesium deficiency on mast cells and urinary histamine in rats</article-title><source>Br J Exp Pathol</source><year>1963</year><volume>44</volume><fpage>151</fpage><lpage>155</lpage><pub-id pub-id-type="pmid">13968527</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Del Castillo</surname><given-names>J</given-names></name><name><surname>Engbaek</surname><given-names>L</given-names></name></person-group><article-title>The nature of the neuromuscular block produced by magnesium</article-title><source>J Physiol</source><year>1954</year><volume>124</volume><fpage>370</fpage><lpage>384</lpage><pub-id pub-id-type="pmid">13175138</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Classen</surname><given-names>HG</given-names></name><name><surname>Jacob</surname><given-names>R</given-names></name><name><surname>Schimatschek</surname><given-names>H</given-names></name></person-group><article-title>Interaction of magnesium with direct and indirect-acting sympathomimetic amines</article-title><source>Magnes Bull</source><year>1987</year><volume>9</volume><fpage>80</fpage><lpage>87</lpage></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kowal</surname><given-names>A</given-names></name><name><surname>Panaszek</surname><given-names>B</given-names></name><name><surname>Barg</surname><given-names>W</given-names></name><name><surname>Obojski</surname><given-names>A</given-names></name></person-group><article-title>The use of magnesium in bronchial asthma: a new approach to an old problem</article-title><source>Arch Immunol Ther Exp (Warsz)</source><year>2007</year><volume>55</volume><fpage>35</fpage><lpage>39</lpage><pub-id pub-id-type="pmid">17277891</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okayama</surname><given-names>H</given-names></name><name><surname>Aikawa</surname><given-names>T</given-names></name><name><surname>Okayama</surname><given-names>M</given-names></name><name><surname>Sasaki</surname><given-names>H</given-names></name><name><surname>Mue</surname><given-names>S</given-names></name><name><surname>Takishima</surname><given-names>T</given-names></name></person-group><article-title>Bronchodilating effect of intravenous magnesium sulfate in bronchial asthma</article-title><source>JAMA</source><year>1987</year><volume>257</volume><fpage>1076</fpage><lpage>1078</lpage><pub-id pub-id-type="pmid">3806898</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McNamara</surname><given-names>RM</given-names></name><name><surname>Spivey</surname><given-names>WH</given-names></name><name><surname>Skobeloff</surname><given-names>E</given-names></name><name><surname>Jacubowitz</surname><given-names>S</given-names></name></person-group><article-title>Intravenous magnesium sulfate in the management of acute respiratory failure complicating asthma</article-title><source>Ann Emerg Med</source><year>1989</year><volume>18</volume><fpage>197</fpage><lpage>199</lpage><pub-id pub-id-type="pmid">2916786</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skobeloff</surname><given-names>EM</given-names></name><name><surname>Spivey</surname><given-names>WH</given-names></name><name><surname>McNamara</surname><given-names>RM</given-names></name><name><surname>Greenspon</surname><given-names>L</given-names></name></person-group><article-title>Intravenous magnesium sulfate for the treatment of acute asthma in the emergency department</article-title><source>JAMA</source><year>1989</year><volume>262</volume><fpage>1210</fpage><lpage>1213</lpage><pub-id pub-id-type="pmid">2761061</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="webpage"><article-title>Global Strategy for Asthma Management and Prevention</article-title><source>Global Initiative for Asthma (GINA)</source><comment>Updated 2010</comment><comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://www.ginasthma.com">http://www.ginasthma.com</ext-link></comment></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="book"><article-title>Expert Panel Report 3 (EPR3): Guidelines for the Diagnosis and Management of Asthma : summary report 2007</article-title><source>National Asthma Education and Prevention Program (National Heart Lung and Blood Institute)</source><publisher-loc>Bethesda, MD</publisher-loc><publisher-name>U.S. Dept. of Health and Human Services, National Institues of Health, National Heart, Lung, and Blood Institute</publisher-name><comment>Updated 2008</comment><comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm">http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm</ext-link></comment></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="webpage"><article-title>British Guideline on the Management of Asthma 2008</article-title><source>British Thoracic Society, Scottish Intercollegiate Guidelines Network</source><comment>Revised 2011</comment><comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://www.brit-thoracic.org.uk/guidelines/asthmaguidelines.aspx">http://www.brit-thoracic.org.uk/guidelines/asthmaguidelines.aspx</ext-link></comment></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jadad</surname><given-names>AR</given-names></name><name><surname>Moore</surname><given-names>RA</given-names></name><name><surname>Carroll</surname><given-names>D</given-names></name><name><surname>Jenkinson</surname><given-names>C</given-names></name><name><surname>Reynolds</surname><given-names>DJ</given-names></name><name><surname>Gavaghan</surname><given-names>DJ</given-names></name><name><surname>McQuay</surname><given-names>HJ</given-names></name></person-group><article-title>Assessing the quality of reports of randomized clinical trials: is blinding necessary?</article-title><source>Control Clin Trials</source><year>1996</year><volume>17</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">8721797</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Green</surname><given-names>SM</given-names></name><name><surname>Rothrock</surname><given-names>SG</given-names></name></person-group><article-title>Intravenous magnesium for acute asthma: failure to decrease emergency treatment duration or need for hospitalization</article-title><source>Ann Emerg Med</source><year>1992</year><volume>21</volume><fpage>260</fpage><lpage>265</lpage><pub-id pub-id-type="pmid">1536485</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>AK</given-names></name><name><surname>Gaur</surname><given-names>S</given-names></name><name><surname>Kumar</surname><given-names>R</given-names></name></person-group><article-title>A randomized controlled trial of intravenous magnesium sulphate as an adjunct to standard therapy in acute severe asthma</article-title><source>Iran J Allergy Asthma Immunol</source><year>2008</year><volume>7</volume><fpage>221</fpage><lpage>229</lpage><pub-id pub-id-type="pmid">19052352</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kokturk</surname><given-names>N</given-names></name><name><surname>Turktas</surname><given-names>H</given-names></name><name><surname>Kara</surname><given-names>P</given-names></name><name><surname>Mullaoglu</surname><given-names>S</given-names></name><name><surname>Yilmaz</surname><given-names>F</given-names></name><name><surname>Karamercan</surname><given-names>A</given-names></name></person-group><article-title>A randomized clinical trial of magnesium sulphate as a vehicle for nebulized salbutamol in the treatment of moderate to severe asthma attacks</article-title><source>Pulm Pharmacol Ther</source><year>2005</year><volume>18</volume><fpage>416</fpage><lpage>421</lpage><pub-id pub-id-type="pmid">15953743</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohammed</surname><given-names>S</given-names></name><name><surname>Goodacre</surname><given-names>S</given-names></name></person-group><article-title>Intravenous and nebulised magnesium sulphate for acute asthma: systematic review and meta-analysis</article-title><source>Emerg Med J</source><year>2007</year><volume>24</volume><fpage>823</fpage><lpage>830</lpage><pub-id pub-id-type="pmid">18029512</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gallegos-Sol&#x000f3;rzano</surname><given-names>MC</given-names></name><name><surname>P&#x000e9;rez-Padilla</surname><given-names>R</given-names></name><name><surname>Hern&#x000e1;ndez-Zenteno</surname><given-names>RJ</given-names></name></person-group><article-title>Usefulness of inhaled magnesium sulfate in the coadjuvant management of severe asthma crisis in an emergency department</article-title><source>Pulm Pharmacol Ther</source><year>2010</year><volume>23</volume><fpage>432</fpage><lpage>437</lpage><pub-id pub-id-type="pmid">20416389</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bradshaw</surname><given-names>TA</given-names></name><name><surname>Matusiewicz</surname><given-names>SP</given-names></name><name><surname>Crompton</surname><given-names>GK</given-names></name><name><surname>Innes</surname><given-names>JA</given-names></name><name><surname>Greening</surname><given-names>AP</given-names></name></person-group><article-title>Intravenous magnesium sulphate provides no additive benefit to standard management in acute asthma</article-title><source>Respir Med</source><year>2008</year><volume>102</volume><fpage>143</fpage><lpage>149</lpage><pub-id pub-id-type="pmid">17869079</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rowe</surname><given-names>BH</given-names></name><name><surname>Bretzlaff</surname><given-names>JA</given-names></name><name><surname>Bourdon</surname><given-names>C</given-names></name><name><surname>Bota</surname><given-names>GW</given-names></name><name><surname>Camargo</surname><given-names>CA</given-names><suffix>Jr</suffix></name></person-group><article-title>Magnesium sulfate for treating exacerbations of acute asthma in the emergency department</article-title><source>Cochrane Database Syst Rev</source><year>2000</year><fpage>CD001490</fpage><pub-id pub-id-type="pmid">10796650</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodrigo</surname><given-names>G</given-names></name><name><surname>Rodrigo</surname><given-names>C</given-names></name><name><surname>Burschtin</surname><given-names>O</given-names></name></person-group><article-title>Efficacy of magnesium sulfate in acute adult asthma: a meta-analysis of randomized trials</article-title><source>Am J Emerg Med</source><year>2000</year><volume>18</volume><fpage>216</fpage><lpage>221</lpage><pub-id pub-id-type="pmid">10750936</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blitz</surname><given-names>M</given-names></name><name><surname>Blitz</surname><given-names>S</given-names></name><name><surname>Beasely</surname><given-names>R</given-names></name><name><surname>Diner</surname><given-names>BM</given-names></name><name><surname>Hughes</surname><given-names>R</given-names></name><name><surname>Knopp</surname><given-names>JA</given-names></name><name><surname>Rowe</surname><given-names>BH</given-names></name></person-group><article-title>Inhaled magnesium sulfate in the treatment of acute asthma</article-title><source>Cochrane Database Syst Rev</source><year>2005</year><fpage>CD003898</fpage></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aggarwal</surname><given-names>P</given-names></name><name><surname>Sharad</surname><given-names>S</given-names></name><name><surname>Handa</surname><given-names>R</given-names></name><name><surname>Dwiwedi</surname><given-names>SN</given-names></name><name><surname>Irshad</surname><given-names>M</given-names></name></person-group><article-title>Comparison of nebulised magnesium sulphate and salbutamol combined with salbutamol alone in the treatment of acute bronchial asthma: a randomised study</article-title><source>Emerg Med J</source><year>2006</year><volume>23</volume><fpage>358</fpage><lpage>362</lpage><pub-id pub-id-type="pmid">16627836</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elliott</surname><given-names>JP</given-names></name><name><surname>Lewis</surname><given-names>DF</given-names></name><name><surname>Morrison</surname><given-names>JC</given-names></name><name><surname>Garite</surname><given-names>TJ</given-names></name></person-group><article-title>In defense of magnesium sulfate</article-title><source>Obstet Gynecol</source><year>2009</year><volume>113</volume><fpage>1341</fpage><lpage>1348</lpage><pub-id pub-id-type="pmid">19461432</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mathew</surname><given-names>R</given-names></name><name><surname>Altura</surname><given-names>BM</given-names></name></person-group><article-title>Magnesium and the lungs</article-title><source>Magnesium</source><year>1988</year><volume>7</volume><fpage>173</fpage><lpage>187</lpage><pub-id pub-id-type="pmid">3072451</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tiffany</surname><given-names>BR</given-names></name><name><surname>Berk</surname><given-names>WA</given-names></name><name><surname>Todd</surname><given-names>IK</given-names></name><name><surname>White</surname><given-names>SR</given-names></name></person-group><article-title>Magnesium bolus or infusion fails to improve expiratory flow in acute asthma exacerbations</article-title><source>Chest</source><year>1993</year><volume>104</volume><fpage>831</fpage><lpage>834</lpage><pub-id pub-id-type="pmid">8365297</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McLaughlin</surname><given-names>SA</given-names></name><name><surname>McKinney</surname><given-names>PE</given-names></name></person-group><article-title>Antacid-induced hypermagnesemia in a patient with normal renal function and bowel obstruction</article-title><source>Ann Pharmacother</source><year>1998</year><volume>32</volume><fpage>312</fpage><lpage>315</lpage><pub-id pub-id-type="pmid">9533062</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Onishi</surname><given-names>S</given-names></name><name><surname>Yoshino</surname><given-names>S</given-names></name></person-group><article-title>Cathartic-induced fatal hypermagnesemia in the elderly</article-title><source>Intern Med</source><year>2006</year><volume>45</volume><fpage>207</fpage><lpage>210</lpage><pub-id pub-id-type="pmid">16543690</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schoeffel</surname><given-names>RE</given-names></name><name><surname>Anderson</surname><given-names>SD</given-names></name><name><surname>Altounyan</surname><given-names>RE</given-names></name></person-group><article-title>Bronchial hyperreactivity in response to inhalation of ultrasonically nebulised solutions of distilled water and saline</article-title><source>Br Med J (Clin Res Ed)</source><year>1981</year><volume>283</volume><fpage>1285</fpage><lpage>1287</lpage></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boulet</surname><given-names>LP</given-names></name><name><surname>Legris</surname><given-names>C</given-names></name><name><surname>Thibault</surname><given-names>L</given-names></name><name><surname>Turcotte</surname><given-names>H</given-names></name></person-group><article-title>Comparative bronchial responses to hyperosmolar saline and methacholine in asthma</article-title><source>Thorax</source><year>1987</year><volume>42</volume><fpage>953</fpage><lpage>958</lpage><pub-id pub-id-type="pmid">3438883</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hill</surname><given-names>J</given-names></name><name><surname>Britton</surname><given-names>J</given-names></name></person-group><article-title>Dose-response relationship and time-course of the effect of inhaled magnesium sulphate on airflow in normal and asthmatic subjects</article-title><source>Br J Clin Pharmacol</source><year>1995</year><volume>40</volume><fpage>539</fpage><lpage>544</lpage><pub-id pub-id-type="pmid">8703659</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Britton</surname><given-names>J</given-names></name><name><surname>Pavord</surname><given-names>I</given-names></name><name><surname>Richards</surname><given-names>K</given-names></name><name><surname>Wisniewski</surname><given-names>A</given-names></name><name><surname>Knox</surname><given-names>A</given-names></name><name><surname>Lewis</surname><given-names>S</given-names></name><name><surname>Tattersfield</surname><given-names>A</given-names></name><name><surname>Weiss</surname><given-names>S</given-names></name></person-group><article-title>Dietary magnesium, lung function, wheezing, and airway hyperreactivity in a random adult population sample</article-title><source>Lancet</source><year>1994</year><volume>344</volume><fpage>357</fpage><lpage>362</lpage><pub-id pub-id-type="pmid">7914305</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McLean</surname><given-names>RM</given-names></name></person-group><article-title>Magnesium and its therapeutic uses: a review</article-title><source>Am J Med</source><year>1994</year><volume>96</volume><fpage>63</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">8304365</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kazaks</surname><given-names>AG</given-names></name><name><surname>Uriu-Adams</surname><given-names>JY</given-names></name><name><surname>Albertson</surname><given-names>TE</given-names></name><name><surname>Shenoy</surname><given-names>SF</given-names></name><name><surname>Stern</surname><given-names>JS</given-names></name></person-group><article-title>Effect of oral magnesium supplementation on measures of airway resistance and subjective assessment of asthma control and quality of life in men and women with mild to moderate asthma: a randomized placebo controlled trial</article-title><source>J Asthma</source><year>2010</year><volume>47</volume><fpage>83</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">20100026</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gontijo-Amaral</surname><given-names>C</given-names></name><name><surname>Ribeiro</surname><given-names>MA</given-names></name><name><surname>Gontijo</surname><given-names>LS</given-names></name><name><surname>Condino-Neto</surname><given-names>A</given-names></name><name><surname>Ribeiro</surname><given-names>JD</given-names></name></person-group><article-title>Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial</article-title><source>Eur J Clin Nutr</source><year>2007</year><volume>61</volume><fpage>54</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">16788707</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zervas</surname><given-names>E</given-names></name><name><surname>Papatheodorou</surname><given-names>G</given-names></name><name><surname>Psathakis</surname><given-names>K</given-names></name><name><surname>Panagou</surname><given-names>P</given-names></name><name><surname>Georgatou</surname><given-names>N</given-names></name><name><surname>Loukides</surname><given-names>S</given-names></name></person-group><article-title>Reduced intracellular Mg concentrations in patients with acute asthma</article-title><source>Chest</source><year>2003</year><volume>123</volume><fpage>113</fpage><lpage>118</lpage><pub-id pub-id-type="pmid">12527611</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rowe</surname><given-names>BH</given-names></name><name><surname>Camargo</surname><given-names>CA</given-names><suffix>Jr</suffix></name></person-group><article-title>The use of magnesium sulfate in acute asthma: rapid uptake of evidence in North American emergency departments</article-title><source>J Allergy Clin Immunol</source><year>2006</year><volume>117</volume><fpage>53</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">16387584</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schuh</surname><given-names>S</given-names></name><name><surname>Macias</surname><given-names>C</given-names></name><name><surname>Freedman</surname><given-names>SB</given-names></name><name><surname>Plint</surname><given-names>AC</given-names></name><name><surname>Zorc</surname><given-names>JJ</given-names></name><name><surname>Bajaj</surname><given-names>L</given-names></name><name><surname>Black</surname><given-names>KJ</given-names></name><name><surname>Johnson</surname><given-names>DW</given-names></name><name><surname>Boutis</surname><given-names>K</given-names></name></person-group><article-title>North American practice patterns of intravenous magnesium therapy in severe acute asthma in children</article-title><source>Acad Emerg Med</source><year>2010</year><volume>17</volume><fpage>1189</fpage><lpage>1196</lpage><pub-id pub-id-type="pmid">21175517</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>LA</given-names></name><name><surname>Goodacre</surname><given-names>S</given-names></name></person-group><article-title>Magnesium sulphate in the treatment of acute asthma: evaluation of current practice in adult emergency departments</article-title><source>Emerg Med J</source><year>2009</year><volume>26</volume><fpage>783</fpage><lpage>785</lpage><pub-id pub-id-type="pmid">19850799</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Babl</surname><given-names>FE</given-names></name><name><surname>Sheriff</surname><given-names>N</given-names></name><name><surname>Borland</surname><given-names>M</given-names></name><name><surname>Acworth</surname><given-names>J</given-names></name><name><surname>Neutze</surname><given-names>J</given-names></name><name><surname>Krieser</surname><given-names>D</given-names></name><name><surname>Ngo</surname><given-names>P</given-names></name><name><surname>Schutz</surname><given-names>J</given-names></name><name><surname>Thomson</surname><given-names>F</given-names></name><name><surname>Cotterell</surname><given-names>E</given-names></name><name><surname>Jamison</surname><given-names>S</given-names></name><name><surname>Francis</surname><given-names>P</given-names></name></person-group><article-title>Paediatric acute asthma management in Australia and New Zealand: practice patterns in the context of clinical practice guidelines</article-title><source>Arch Dis Child</source><year>2008</year><volume>93</volume><fpage>307</fpage><lpage>312</lpage><pub-id pub-id-type="pmid">18356383</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohta</surname><given-names>K</given-names></name><name><surname>Makino</surname><given-names>S</given-names></name><name><surname>Adachi</surname><given-names>M</given-names></name><name><surname>Kihara</surname><given-names>N</given-names></name><name><surname>Nakajima</surname><given-names>S</given-names></name><name><surname>Nishima</surname><given-names>S</given-names></name><name><surname>Fukuda</surname><given-names>T</given-names></name><name><surname>Miyamoto</surname><given-names>T</given-names></name></person-group><article-title>Prospective survey on safety evaluation of injectable methylxanthines in Japan</article-title><source>Allergol Int</source><year>2006</year><volume>55</volume><fpage>295</fpage><lpage>299</lpage><pub-id pub-id-type="pmid">17075270</pub-id></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silverman</surname><given-names>RA</given-names></name><name><surname>Osborn</surname><given-names>H</given-names></name><name><surname>Runge</surname><given-names>J</given-names></name><name><surname>Gallagher</surname><given-names>EJ</given-names></name><name><surname>Chiang</surname><given-names>W</given-names></name><name><surname>Feldman</surname><given-names>J</given-names></name><name><surname>Gaeta</surname><given-names>T</given-names></name><name><surname>Freeman</surname><given-names>K</given-names></name><name><surname>Levin</surname><given-names>B</given-names></name><name><surname>Mancherje</surname><given-names>N</given-names></name><name><surname>Scharf</surname><given-names>S</given-names></name></person-group><article-title>IV magnesium sulfate in the treatment of acute severe asthma: a multicenter randomized controlled trial</article-title><source>Chest</source><year>2002</year><volume>122</volume><fpage>489</fpage><lpage>497</lpage><pub-id pub-id-type="pmid">12171821</pub-id></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bijani</surname><given-names>K</given-names></name><name><surname>Moghadamnia</surname><given-names>AA</given-names></name><name><surname>Islami Khalili</surname><given-names>E</given-names></name></person-group><article-title>Intravenous magnesium sulfate as an adjunct in the treatment of severe asthmatic patients non-responding to conventional therapy</article-title><source>Acta Medica Iranica</source><year>2001</year><volume>39</volume><fpage>219</fpage><lpage>221</lpage></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Porter</surname><given-names>RS</given-names></name><name><surname>Nester</surname><given-names>BA</given-names></name><name><surname>Braitman</surname><given-names>LE</given-names></name><name><surname>Geary</surname><given-names>U</given-names></name><name><surname>Dalsey</surname><given-names>WC</given-names></name></person-group><article-title>Intravenous magnesium is ineffective in adult asthma, a randomized trial</article-title><source>Eur J Emerg Med</source><year>2001</year><volume>8</volume><fpage>9</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">11314826</pub-id></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boonyavorakul</surname><given-names>C</given-names></name><name><surname>Thakkinstian</surname><given-names>A</given-names></name><name><surname>Charoenpan</surname><given-names>P</given-names></name></person-group><article-title>Intravenous magnesium sulfate in acute severe asthma</article-title><source>Respirology</source><year>2000</year><volume>5</volume><fpage>221</fpage><lpage>225</lpage><pub-id pub-id-type="pmid">11022983</pub-id></element-citation></ref><ref id="B46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bloch</surname><given-names>H</given-names></name><name><surname>Silverman</surname><given-names>R</given-names></name><name><surname>Mancherje</surname><given-names>N</given-names></name><name><surname>Grant</surname><given-names>S</given-names></name><name><surname>Jagminas</surname><given-names>L</given-names></name><name><surname>Scharf</surname><given-names>SM</given-names></name></person-group><article-title>Intravenous magnesium sulfate as an adjunct in the treatment of acute asthma</article-title><source>Chest</source><year>1995</year><volume>107</volume><fpage>1576</fpage><lpage>1581</lpage><pub-id pub-id-type="pmid">7781349</pub-id></element-citation></ref><ref id="B47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hughes</surname><given-names>R</given-names></name><name><surname>Goldkorn</surname><given-names>A</given-names></name><name><surname>Masoli</surname><given-names>M</given-names></name><name><surname>Weatherall</surname><given-names>M</given-names></name><name><surname>Burgess</surname><given-names>C</given-names></name><name><surname>Beasley</surname><given-names>R</given-names></name></person-group><article-title>Use of isotonic nebulised magnesium sulphate as an adjuvant to salbutamol in treatment of severe asthma in adults: randomised placebo-controlled trial</article-title><source>Lancet</source><year>2003</year><volume>361</volume><fpage>2114</fpage><lpage>2117</lpage><pub-id pub-id-type="pmid">12826434</pub-id></element-citation></ref><ref id="B48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bessmertny</surname><given-names>O</given-names></name><name><surname>DiGregorio</surname><given-names>RV</given-names></name><name><surname>Cohen</surname><given-names>H</given-names></name><name><surname>Becker</surname><given-names>E</given-names></name><name><surname>Looney</surname><given-names>D</given-names></name><name><surname>Golden</surname><given-names>J</given-names></name><name><surname>Kohl</surname><given-names>L</given-names></name><name><surname>Johnson</surname><given-names>T</given-names></name></person-group><article-title>A randomized clinical trial of nebulized magnesium sulfate in addition to albuterol in the treatment of acute mild-to-moderate asthma exacerbations in adults</article-title><source>Ann Emerg Med</source><year>2002</year><volume>39</volume><fpage>585</fpage><lpage>591</lpage><pub-id pub-id-type="pmid">12023699</pub-id></element-citation></ref><ref id="B49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nannini</surname><given-names>LJ</given-names><suffix>Jr</suffix></name><name><surname>Pendino</surname><given-names>JC</given-names></name><name><surname>Corna</surname><given-names>RA</given-names></name><name><surname>Mannarino</surname><given-names>S</given-names></name><name><surname>Quispe</surname><given-names>R</given-names></name></person-group><article-title>Magnesium sulfate as a vehicle for nebulized salbutamol in acute asthma</article-title><source>Am J Med</source><year>2000</year><volume>108</volume><fpage>193</fpage><lpage>197</lpage><pub-id pub-id-type="pmid">10723972</pub-id></element-citation></ref><ref id="B50"><label>50</label><element-citation publication-type="webpage"><article-title>Asthma Management Handbook</article-title><source>National Asthma Council Australia</source><year>2006</year><comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://www.nationalasthma.org.au/uploads/handbook/370-amh2006_web_5.pdf">http://www.nationalasthma.org.au/uploads/handbook/370-amh2006_web_5.pdf</ext-link></comment></element-citation></ref><ref id="B51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jindal</surname><given-names>SK</given-names></name><name><surname>Gupta</surname><given-names>D</given-names></name><name><surname>Aggarwal</surname><given-names>AN</given-names></name><name><surname>Agarwal</surname><given-names>R</given-names></name></person-group><article-title>Guidelines for management of asthma at primary and secondary levels of health care in India</article-title><source>Indian J Chest Dis Allied Sci</source><year>2005</year><volume>47</volume><fpage>309</fpage><lpage>343</lpage><pub-id pub-id-type="pmid">16255405</pub-id></element-citation></ref><ref id="B52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohta</surname><given-names>K</given-names></name><name><surname>Yamaguchi</surname><given-names>M</given-names></name><name><surname>Akiyama</surname><given-names>K</given-names></name><name><surname>Adachi</surname><given-names>M</given-names></name><name><surname>Ichinose</surname><given-names>M</given-names></name><name><surname>Takahashi</surname><given-names>K</given-names></name><name><surname>Nishimuta</surname><given-names>T</given-names></name><name><surname>Morikawa</surname><given-names>A</given-names></name><name><surname>Nishima</surname><given-names>S</given-names></name></person-group><article-title>Japanese guideline for adult asthma</article-title><source>Allergol Int</source><year>2011</year><volume>60</volume><fpage>115</fpage><lpage>145</lpage><pub-id pub-id-type="pmid">21636963</pub-id></element-citation></ref><ref id="B53"><label>53</label><element-citation publication-type="webpage"><article-title>Korean Asthma Management Guideline for Adults</article-title><source>Korean Academy of Asthma, Allergy and Clinical Immunology</source><comment>Revised 2011</comment><comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://www.allergy.or.kr/file/2011_new.pdf">http://www.allergy.or.kr/file/2011_new.pdf</ext-link></comment></element-citation></ref></ref-list></back><floats-group><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Summary of randomized placebo-controlled trials for efficacy of intravenous MgSO<sub>4</sub> in acute exacerbation of adult asthmatics</p></caption><graphic xlink:href="apa-2-76-i001"/><table-wrap-foot><fn><p>MgSO<sub>4</sub>, magnesium sulfate; FEV1, forced expiratory volume in 1 sec; PEFR, peak expiratory flow rate; ED, emergency department.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Summary of randomized placebo-controlled trials for efficacy of nebulized MgSO<sub>4</sub> in acute exacerbation of adult asthmatics</p></caption><graphic xlink:href="apa-2-76-i002"/><table-wrap-foot><fn><p>MgSO<sub>4</sub>, magnesium sulfate; FEV1, forced expiratory volume in 1 sec; PEFR, peak expiratory flow rate.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Summary of systematic reviews and meta-analyses: randomized placebo-controlled trials for the efficacy of MgSO<sub>4</sub> as an adjunct therapy for acute asthma in adults</p></caption><graphic xlink:href="apa-2-76-i003"/><table-wrap-foot><fn><p>MgSO<sub>4</sub>, magnesium sulfate; IV, intravenous; SMD, standardized mean difference; RR, relative risk; FEV1, forced expiratory volume in 1 sec; PEFR, peak expiratory flow rate; OR, odds ratio; WMD, weighted mean difference.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T4" position="float"><label>Table 4</label><caption><p>Current guideline recommendations regarding the use of MgSO<sub>4</sub> for acute exacerbation of adult asthma</p></caption><graphic xlink:href="apa-2-76-i004"/><table-wrap-foot><fn><p>MgSO<sub>4</sub>, magnesium sulfate; GINA, Global Initiative for Asthma; NAEPP, National Asthma Education and Prevention Program; BTS, British Thoracic Society; SIGN, Scottish Intercollegiate Guidelines Network; FEV1, forced expiratory volume in 1 sec; SABA, short-acting beta-agonist.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T5" position="float"><label>Table 5</label><caption><p>Summary of surveys for practice patterns in the emergency departments regarding the use of MgSO<sub>4</sub></p></caption><graphic xlink:href="apa-2-76-i005"/><table-wrap-foot><fn><p>MgSO<sub>4</sub>, magnesium sulfate; ED, emergency department; IV, intravenous; CPG, current practice guideline.</p></fn></table-wrap-foot></table-wrap></floats-group></article>